Wissenschaftliche Verweise zur Irreversiblen Elektroporation

 

Focal irreversible electroporation for prostate cancer: functional outcome and short-term oncological control

F Ting, M Tran, M Boehm et at.
 
 
 
 
Focal Therapy of Prostate Cancer Using Irreversible Electroporation
 
Valerio, Massimo, Hashim U. Ahmed, and Mark Emberton.
 

 

Irreversible electroporation treatment for prostate adenocarcinomas: a safety outcome study

Our presentation on SIR 2015 Annual Scientific Meeting

Tomihama, R. T., E.Guenther, M.K.Stehling

 
 
Prostate Cancer Treatment with Irreversible Electroporation

Presentation of our numbers on the Global Congress on Prostate Cancer 2015

M.K.Stehling et al

https://www.prostata-center.de/images/IfbD_Prosca2015.pdf

 

Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer.

Valerio, M., et al.

Nature - Prostate cancer and prostatic diseases (2014).

https://www.nature.com/pcan/journal/vaop/ncurrent/full/pcan201433a.html

 

Prostate cancer: Irreversible electroporation is a safe and feasible option for focal therapy.

Fenner, Annette.

Nature Reviews Urology (2014).

https://www.nature.com/nrurol/journal/vaop/ncurrent/full/nrurol.2014.260.html

 

Improved Local and Systemic Anti-Tumor Efficacy for Irreversible Electroporation in Immunocompetent versus Immunodeficient Mice

Robert E. Neal II et al.

PLoS ONE;May2013, Vol. 8 Issue 5, p1

www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0064559

 

Image Guides Prostate Cancer Treatments

G.Onik et al

Book 2014

https://link.springer.com/chapter/10.1007/978-3-642-40429-0_20

 

In Vivo Validation of Irreversible Electroporation Electric Field Threshold for Prostate Tissue

Robert E. Neal et al

https://proceedings.asmedigitalcollection.asme.org/proceeding.aspx?articleid=1820172

 

A prospective development study investigating focal irreversible electroporation in men with localised prostate cancer: Nanoknife Electroporation Ablation Trial (NEAT).

Valerio, Massimo, et al.

Contemporary clinical trials (2014).

https://www.sciencedirect.com/science/article/pii/S1551714414001153

 

First patient experience focal therapy of prostate cancer

G Onik, B Rubinsky

Irreversible Electroporation, 2010 - Springer

https://link.springer.com/chapter/10.1007/978-3-642-05420-4_10

 

Irreversible electroporation in medicine.

Rubinsky B.

Technol Cancer Res Treat. 2007 Aug;6(4):255-60.

https://www.ncbi.nlm.nih.gov
https://www.cs.huji.ac.il/~rubinsky/electroporation/Rubinsky%20TCRT.pdf


Irreversible electroporation: a new ablation modality--clinical implications.

Rubinsky B, Onik G, Mikus P.

Technol Cancer Res Treat. 2007 Feb;6(1):37-48.

https://www.ncbi.nlm.nih.gov
https://www.cs.huji.ac.il/~rubinsky/electroporation/IRE-TCRT%20paper.pdf


Imaging guided percutaneous irreversible electroporation: ultrasound and immunohistological correlation.

Lee EW, Loh CT, Kee ST.

Technol Cancer Res Treat. 2007 Aug;6(4):287-94.

https://www.ncbi.nlm.nih.gov

 

Irreversible electroporation: implications for prostate ablation.

Onik G, Mikus P, Rubinsky B.

Technol Cancer Res Treat. 2007 Aug;6(4):295-300.

https://www.ncbi.nlm.nih.gov
https://www.cs.huji.ac.il/~rubinsky/electroporation/Onik%20et%20al.%20TCRT.pdf


Optimal parameters for the destruction of prostate cancer using irreversible electroporation.

Rubinsky J, Onik G, Mikus P, Rubinsky B.

J Urol. 2008 Dec;180(6):2668-74. Epub 2008 Oct 31.

https://www.ncbi.nlm.nih.gov
https://www.cs.huji.ac.il/~rubinsky/electroporation/Yoni.pdf


Irreversible Electroporation: A Novel Image-Guided Cancer Therapy.

Lee EW, Thai S, Kee ST.

Gut Liver. 2010 Sep;4(Suppl. 1):S99-S104. Epub 2010 Sep 10.
https://www.ncbi.nlm.nih.gov
https://pdf.medrang.co.kr/ekjg/ekjg004-Suppl.1-16.pdf

 

Irreversible electroporation (IRE), a novel technique for focal ablation

of prostate cancer (PCa): Results of a interim pilot safety study in low risk patients with PCa

Brausi M.A.1, Giliberto G.L.1

 

Investigation of the safety of irreversible electroporation in humans

KR Thomson, W Cheung, SJ Ellis, D Federma

Journal of Vascular and …, 2011 – Elsevier

 

Non-Thermal Irreversible Electroporation: Fundamentals, Applications and Challenges.

Golberg, Alexander, and M. Yarmush.

IEEE transactions on bio-medical engineering 60.3 (2013): 707-714

https://europepmc.org/abstract/MED/23314769

 

 

Wissenschaftliche Verweise zur transperinealen 3D-Prostatabiopsie

Clinical staging of prostate cancer: a computer-simulated study of transperineal prostate biopsy.

Crawford ED, Wilson SS, Torkko KC, et al.
BJU Int. 2005 Nov;96(7):999-1004.
https://www.ncbi.nlm.nih.gov


Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management.
Onik G, Miessau M, Bostwick DG.
J Clin Oncol. 2009 Sep 10;27(26):4321-6. Epub 2009 Aug 3.
https://www.ncbi.nlm.nih.gov
https://jco.ascopubs.org


High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series.
Walz J, Graefen M, Chun FK, Erbersdobler A, et al.
Eur Urol. 2006 Sep;50(3):498-505. Epub 2006 Mar 29.
https://www.ncbi.nlm.nih.gov

Beyond Diagnosis: Evolving Prostate Biopsy in the Era of Focal Therapy Prostate Cancer Volume 2011, Article ID 386207

Prostate Biopsy: The Transperineal Approach eau - ebu update series 5 (2007) 241–249

Three-Dimensional Prostate Mapping Biopsy Has a Potentially Significant Impact on Prostate Cancer Management Journal of Clinical Oncology VOLUME 27 # NUMBER 26 # SEPTEMBER 10 2009

E. D. Crawford, S. S. Wilson, K. C. Torkko et al., "Clinical staging of prostate cancer: a computer-simulated study of transperineal prostate biopsy," BJU International, vol. 96, no. 7, pp. 999–1004, 2005.

G. Onik and W. Barzell, "Transperineal 3D mapping biopsy of the prostate: an essential tool in selecting patients for focal prostate cancer therapy," Urologic Oncology, vol. 26, no. 5, pp. 506–510, 2008.

G. Onik, M. Miessau, and D. G. Bostwick, "Threedimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management," Journal of Clinical Oncology, vol. 27, no. 26, pp. 4321–4326, 2009.

H. Li, W. Yan, Y. Zhou, Z. Ji, and J. Chen, "Transperineal ultrasound-guided saturation biopsies using 11-region template of prostate: report of 303 cases," Urology, vol. 70, no. 6, pp. 1157–1161, 2007.

M. Tsivian, M. Kimura, L. Sun, V. Mouraviev, J. M. Mayes, and T. J. Polascik, "Predicting unilateral prostate cancer on routine diagnostic biopsy: sextant vs extended," BJU International, vol. 105, no. 8, pp. 1089–1092, 2010.

V. Mouraviev, J. M. Mayes, L. Sun, J. F. Madden, J. W. Moul, and T. J. Polascik, "Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer," Cancer, vol. 110, no. 4, pp. 906–910, 2007.

J. M. Mayes, V. Mouraviev, L. Sun, M. Tsivian, J. F. Madden, and T. J. Polascik, "Can the conventional sextant prostate biopsy accurately predict unilateral prostate cancer in lowrisk, localized, prostate cancer?" Urologic Oncology. In press.

R. T. Schulte, D. P. Wood, S. Daignault, R. B. Shah, and J. T. Wei, "Utility of extended pattern prostate biopsies for tumor localization: pathologic correlations after radical prostatectomy," Cancer, vol. 113, no. 7, pp. 1559–1565, 2008.

T. J. Polascik, J. M. Mayes, F. R. Schroeck et al., "Patient selection for hemiablative focal therapy of prostate cancer: variables predictive of tumor unilaterality based upon radical prostatectomy," Cancer, vol. 115, no. 10, pp. 2104–2110, 2009.

M. K. Buyyounouski, E. M. Horwitz, A. L. Hanlon, R. G. Uzzo, G. E. Hanks, and A. Pollack, "Positive prostate biopsy laterality and implications for staging," Urology, vol. 62, no. 2, pp. 298–303, 2003.

C. D. Scales Jr., J. C. Presti Jr., C. J. Kane et al., "Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy—results from the SEARCH database," Journal of Urology, vol. 178, no. 4, pp. 1249–1252, 2007.

M. Tsivian, D. M. Moreira, L. Sun et al., "Biopsy accuracy in identifying unilateral prostate cancer depends on prostate weight," Urologic Oncology. In press.

W. E. Barzell and M. R. Melamed, "Appropriate patient selection in the focal treatment of prostate cancer: the role of transperineal 3-dimensional pathologic mapping of the prostate—a 4-year experience," Urology, vol. 70, no. 6, pp. S27–S35, 2007.

A. O. Sartor, H. Hricak, T. M. Wheeler et al., "Evaluating localized prostate cancer and identifying candidates for focaltherapy," Urology, vol. 72, no. 6, pp. S12–S24, 2008.

M. Watanabe, T. Hayashi, T. Tsushima, S. Irie, T. Kaneshige, and H. Kumon, "Extensive biopsy using a combined transperineal and transrectal approach to improve prostate cancer detection," International Journal of Urology, vol. 12, no. 11, pp. 959–963, 2005.

S. Kawakami, N. Hyochi, J. Yonese et al., "Three-dimensionalcombination of transrectal and transperineal biopsies for efficient detection of stage T1c prostate cancer," International Journal of Clinical Oncology, vol. 11, no. 2, pp. 127–132, 2006.

N. Numao, S. Kawakami, M. Yokoyama et al., "Improved accuracy in predicting the presence of Gleason pattern 4/5 prostate cancer by three-dimensional 26-core systematic biopsy," European Urology, vol. 52, no. 6, pp. 1663–1669, 2007.

S. Kawakami, T. Okuno, J. Yonese et al., "Optimal sampling sites for repeat prostate biopsy: a recursive partitioning analysis of three-dimensional 26-core systematic biopsy," European Urology, vol. 51, no. 3, pp. 675–683, 2007.7

N. Numao, S. Kawakami, J. Yonese et al., "Three-dimensional 26-core biopsy-based patient selection criteria for nervesparing radical prostatectomy," International Journal of Urology, vol. 15, no. 12, pp. 1061–1066, 2008.

Arumainayagam, Nimalan, et al. "Multiparametric MR Imaging for Detection of Clinically Significant Prostate Cancer: A Validation Cohort Study with Transperineal Template Prostate Mapping as the Reference Standard." Radiology (2013).

Beyond Diagnosis: Evolving Prostate Biopsy in the Era of Focal Therapy Prostate Cancer Volume 2011, Article ID 386207

Barqawi, Al B., et al. "The role of 3-dimensional mapping biopsy in decision making for treatment of apparent early stage prostate cancer." The Journal of urology 186.1 (2011): 80-85.https://www.sciencedirect.com/science/article/pii/S0022534711032514

Crawford, E. David, et al. "Clinical‐Pathologic Correlation Between Transperineal Mapping Biopsies of the Prostate and Three‐Dimensional Reconstruction of Prostatectomy Specimens." The Prostate 73.7 (2013): 778-787. https://onlinelibrary.wiley.com/doi/10.1002/pros.22622/full

 

Wissenschaftliche Verweise zur MRT und der Bildgebenden Diagnostik der Prostata

 

Magnetic Resonance Imaging for the Detection, Localisation, and Characterisation of Prostate Cancer: Recommendations from a European Consensus Meeting https://www.sciencedirect.com/science/article/pii/S0302283810011875

MRI in addition to or as a substitute for prostate biopsy: The clinician's point of view Diagnostic and Interventional Imaging Volume 93, Issue 4, April 2012, Pages 262 67 Urologic oncology

The Value of Endorectal MRI in the Early Diagnosis of Prostate Cancer European Urology Volume 44, Issue 2, August 2003, Pages 201 08

Multiparametric prostate MRI using pelvic phased-array coil: Utility for tumor detection prior to biopsy Urologic Oncology: Seminars and Original Investigations

How Good is MRI at Detecting and Characterising Cancer within the Prostate? European Urology, Volume 50, Issue 6, Pages 1163-1175

The combination of multi-voxel MR spectroscopy with MR imaging improve the diagnostic accuracy for localization of prostate cancer. Hasumi M, Suzuki K, Taketomi A, Matsui H, Yamamoto T, Ito K, Kurokawa K, Aoki J, Endo K, Yamanaka H

Prostate cancer detection with multi-parametric MRI: Logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI Journal of Magnetic Resonance Imaging Volume 30, Issue 2, pages 327 34, August 2009

 

Wysock, James S., et al. "Predictive value of negative 3T multiparametric magnetic resonance imaging of the prostate on 12‐core biopsy results." BJU international (2016). https://onlinelibrary.wiley.com/doi/10.1111/bju.13427/pdf

 

Thompson, J. E., et al. "The diagnostic performance of multiparametric magnetic resonance imaging to detect significant prostate cancer." The Journal of urology 195.5 (2016): 1428-1435. https://www.sciencedirect.com/science/article/pii/S0022534715051630

Radtke, Jan P., et al. "Multiparametric magnetic resonance imaging (MRI) and MRI–transrectal ultrasound fusion biopsy for index tumor detection: correlation with radical prostatectomy specimen." European urology (2016). https://www.sciencedirect.com/science/article/pii/S0302283816000105

 

Fütterer, Jurgen J., et al. "Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature." European urology 68.6 (2015): 1045-1053.https://www.sciencedirect.com/science/article/pii/S0302283815000366

Prostata-Center



Strahlenberger Straße 110

D-63067 Offenbach am Main



Telefon: 069-50 50 00 980

Fax: 069-50 50 00 98-8



info@prostata-center.de

www.prostata-center.de



Beratungszeiten

Mo. - Fr.: 9.00 - 17.00

Vereinbaren Sie einen Termin mit uns.

069-50 50 00 980

Oder hinterlassen Sie Ihren Namen, Telefonnummer und/oder E-Mail Addresse und wir kontaktieren Sie!

 

Name
E-Mail
Telefon
Ihre Nachricht
 

Oder nutzen Sie unser großes Kontaktformular

Unser IRE/NanoKnife® Flyer

Sie wollen mehr über Irreversible Elektroporation und NanoKnife® erfahren?

Klicken Sie auf das Bild um sich unseren Flyer anzusehen.

  Flyer download

Finden Sie uns auf Facebook

Professor Stehling

Michael Stehling

 

Prof. Dr. med. Dr. phil. Dr. med. habil. Michael K. Stehling - University Professor of Radiology, Jerusalem University Visiting Scholar, University of California in Berkeley, Privatdozent an der LMU München

 

Prof. Stehling war wissenschaftlicher Mitarbeiter von Sir Peter Mansfield, der 2003 für die Entwicklung der Magnetresonanztomographie mit dem Nobelpreis ausgezeichnet wurde. Seit 2010 leitet Prof. Stehling das auf moderne Diagnostik und minimal invasive Therapieverfahren spezialisierte Prostata-Center in Frankfurt am Main/Offenbach.

Dr. med. Stefan Zapf

Stefan Zapf

 

Dr. med. Stefan Zapf studierte Biologe und Humanmedizin an der Universität in Mainz. Hier war er nach der Facharztausbildung sowohl in der diagnostischen und interventionellen Radiologie, als auch in der Strahlentherapie in leitender Position tätig. Seit 2005 leitet er die interventionelle Radiologie des Institutes für Bildgebende Diagnostik und des Prostata-Centers. Zusammen mit Prof. Stehling führte er weltweit die meisten erfolgreichen Interventionen mit gepulsten E-Feld Verfahren durch.